Distinguished in Angiosarcoma of the Scalp

Dr. Thomas J. Galloway

Radiation Oncology
Temple Faculty Practice Plan Inc
3401 N Broad St, 
Philadelphia, PA 
 (801.2 mi)
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
Distinguished in Angiosarcoma of the Scalp
Temple Faculty Practice Plan Inc
3401 N Broad St, 
Philadelphia, PA 
 (801.2 mi)
OverviewInsuranceLocationsClinical Research

Overview

Thomas Galloway is a Radiation Oncologist in Philadelphia, Pennsylvania. Dr. Galloway and is rated as a Distinguished provider by MediFind in the treatment of Angiosarcoma of the Scalp. His top areas of expertise are Head and Neck Squamous Cell Carcinoma (HNSCC), Laryngeal Cancer, Adenoid Cystic Carcinoma, Throat Cancer, and Glossectomy.

His clinical research consists of co-authoring 83 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
University Of Florida College Of Medicine
Specialties
Radiation Oncology
Licenses
Radiology in FL
Hospital Affiliations
Temple University Hospital
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Locations

TEMPLE FACULTY PRACTICE PLAN INC
3401 N Broad St, Philadelphia, PA 19140

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Phase II Randomized Trial of Radiotherapy With or Without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) With TP53 Sequencing
Phase II Randomized Trial of Radiotherapy With or Without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) With TP53 Sequencing
Enrollment Status: Recruiting
Publish Date: August 09, 2024
Intervention Type: Drug, Other, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2
Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Enrollment Status: Active_not_recruiting
Publish Date: January 14, 2025
Intervention Type: Other, Biological, Radiation
Study Drugs: Cetuximab, Durvalumab
Study Phase: Phase 2/Phase 3
A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2024
Intervention Type: Other, Procedure, Drug, Biological, Radiation
Study Drugs: Cisplatin, Nivolumab
Study Phase: Phase 2/Phase 3
A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer
A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer
Enrollment Status: Active_not_recruiting
Publish Date: May 28, 2024
Intervention Type: Biological, Radiation
Study Drug: Cetuximab
Study Phase: Phase 3
A Phase II Trial of Reirradiation Combined With Open Label Pembrolizumab in Patients With Locoregional Inoperable Recurrence or Second Primary Squamous Cell Carcinoma of the Head and Neck (SCCHN)
A Phase II Trial of Reirradiation Combined With Open Label Pembrolizumab in Patients With Locoregional Inoperable Recurrence or Second Primary Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Enrollment Status: Active_not_recruiting
Publish Date: February 07, 2024
Intervention Type: Radiation, Drug
Study Drug: Pembrolizumab
Study Phase: Phase 2
ROMAN: Reduction in Oral Mucositis With Avasopasem Manganese (GC4419) - Phase 3 Trial in Patients Receiving Chemoradiotherapy for Locally-Advanced, Non-Metastatic Head and Neck Cancer
ROMAN: Reduction in Oral Mucositis With Avasopasem Manganese (GC4419) - Phase 3 Trial in Patients Receiving Chemoradiotherapy for Locally-Advanced, Non-Metastatic Head and Neck Cancer
Enrollment Status: Completed
Publish Date: October 24, 2023
Intervention Type: Drug
Study Drug: GC4419
Study Phase: Phase 3
TRYHARD: A Phase II, Randomized, Double Blind, Placebo-Controlled Study of Lapatinib (Tykerb®) for Non-HPV Locally Advanced Head and Neck Cancer With Concurrent Chemoradiation
TRYHARD: A Phase II, Randomized, Double Blind, Placebo-Controlled Study of Lapatinib (Tykerb®) for Non-HPV Locally Advanced Head and Neck Cancer With Concurrent Chemoradiation
Enrollment Status: Completed
Publish Date: October 17, 2023
Intervention Type: Drug, Radiation
Study Drugs: Cisplatin, Lapatinib
Study Phase: Phase 2
A Phase I and Expansion Cohort Study of Adjuvant Cisplatin, Intensity-Modulated Radiotherapy, and MK-3475 (Pembrolizumab) in High-Risk Head and Neck Squamous Cell Carcinoma (HNSCC)
A Phase I and Expansion Cohort Study of Adjuvant Cisplatin, Intensity-Modulated Radiotherapy, and MK-3475 (Pembrolizumab) in High-Risk Head and Neck Squamous Cell Carcinoma (HNSCC)
Enrollment Status: Completed
Publish Date: June 10, 2022
Intervention Type: Drug, Other, Radiation, Biological
Study Drugs: Cisplatin, Pembrolizumab
Study Phase: Phase 1
View 7 Less Clinical Trials

83 Total Publications

International Expert-Based Consensus Definition, Classification Criteria, and Minimum Data Elements for Osteoradionecrosis of the Jaw: An Inter-Disciplinary Modified Delphi Study.
International Expert-Based Consensus Definition, Classification Criteria, and Minimum Data Elements for Osteoradionecrosis of the Jaw: An Inter-Disciplinary Modified Delphi Study.
Journal: International journal of radiation oncology, biology, physics
Published: July 25, 2024
Similar Doctors
Advanced in Angiosarcoma of the Scalp
Dr. Yana P. Goldberg
Radiation Oncology
Advanced in Angiosarcoma of the Scalp
Dr. Yana P. Goldberg
Radiation Oncology

Practice Associates Medical Group

651 Willow Grove St, 
Hackettstown, NJ 
 (61.7 mi)
908-441-1161
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Yana Goldberg is a Radiation Oncologist in Hackettstown, New Jersey. Dr. Goldberg and is rated as a Distinguished provider by MediFind in the treatment of Angiosarcoma of the Scalp. Her top areas of expertise are Endometrial Cancer, Endometrial Stromal Sarcoma, Cervical Cancer, and Neuroendocrine Carcinoma of the Cervix.

Advanced in Angiosarcoma of the Scalp
Dr. Christopher A. Barker
Radiation Oncology
Advanced in Angiosarcoma of the Scalp
Dr. Christopher A. Barker
Radiation Oncology

Msk Monmouth

480 Red Hill Rd, 
Middletown, NJ 
 (58.7 mi)
908-542-3007
Languages Spoken:
English
Offers Telehealth

Christopher Barker is a Radiation Oncologist in Middletown, New Jersey. Dr. Barker and is rated as a Distinguished provider by MediFind in the treatment of Angiosarcoma of the Scalp. His top areas of expertise are Merkel Cell Carcinoma, Melanoma of the Eye, Adenoid Cystic Carcinoma, and Teratocarcinosarcoma.

Advanced in Angiosarcoma of the Scalp
Dr. Joseph M. Pepek
Radiation Oncology | Radiology
Advanced in Angiosarcoma of the Scalp
Dr. Joseph M. Pepek
Radiation Oncology | Radiology

Titan Health Partners LLC

1201 Langhorne Newtown Rd, 
Langhorne, PA 
 (18.1 mi)
732-390-7750
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Joseph Pepek is a Radiation Oncologist and a Radiologist in Langhorne, Pennsylvania. Dr. Pepek and is rated as an Advanced provider by MediFind in the treatment of Angiosarcoma of the Scalp. His top areas of expertise are Familial Prostate Cancer, Lung Cancer, Pleuropulmonary Blastoma, Intraductal Papilloma, and Pancreaticoduodenectomy. Dr. Pepek is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile